Bio-Thera
Solutions, a clinical-stage biopharmaceutical company developing a
pipeline of innovative therapies and a pipeline of biosimilars, today
announced the company will present two posters at the 2018 San Antonio
Breast Cancer Symposium (SABCS) taking place December 4 - 8, 2018 in San
Antonio, Texas.
The first
poster, entitled “BAT8001, a potent anti-Her2 antibody-drug conjugate
with a novel stable linker for the treatment of Her2-positive breast
cancer,” will present preclinical data that highlight advantages of
BAT8001 as a potential treatment for breast cancer patients. An abstract of the presentation is currently available on the SABCS website.
Presentation details are as follows:
|
Poster Session:
|
|
Treatment: Her2-targeted therapy
|
|
Session Date and Time:
|
|
Saturday, December 8, 7:00 am – 9:00 am
|
|
Location:
|
|
Poster Area/Exhibition Hall
|
|
Poster Board Number:
|
|
P6-17-39
|
The second
poster, entitled “BAT8003, a potent anti-Trop-2 antibody-drug conjugate,
for the treatment of Trop-2 positive Triple Negative Breast Cancer,”
will present preclinical data that highlight advantages of BAT8003 as a
potential treatment for triple negative breast cancer patients. An abstract of the presentation is currently available on the SABCS website.
Presentation details are as follows:
|
Poster Session:
|
|
Treatment: Novel Targets and Targeted Agents
|
|
Session Date and Time:
|
|
Saturday, December 8, 7:00 am – 9:00 am
|
|
Location:
|
|
Poster Area/Exhibition Hall
|
|
Poster Board Number:
|
|
P6-20-16
|
About BAT8001
BAT8001 is
an investigational Her2-ADC being evaluated in multiple tumor types.
Her2 is a naturally occurring receptor that is overexpressed in many
types of cancer, including breast cancer and gastric cancer. BAT8001 is
being developed for use as a single agent and in combination with other
agents for the treatment of multiple cancers. BAT8001 is currently
being evaluated in a Phase 3 clinical trial for the treatment of
metastatic breast cancer patients (more information on the trial is
available at http://www.chinadrugtrials.org.cn/ (CTR20180157)).
The BAT8001 clinical study program will expand beyond metastatic
breast cancer to other Her2-positive cancers, including gastric cancer,
over the next 12 months.
About BAT8003
BAT8003 is an
investigational Trop-2-ADC being evaluated in multiple tumor types.
Trop-2 is a naturally occurring receptor that is overexpressed in many
types of cancer, including triple negative breast cancer and gastric
cancer. BAT8003 is being developed for use as a single agent and in
combination with other agents for the treatment of multiple cancers. A
Phase 1 clinical trial evaluating the pharmacodynamics and safety of
BAT8003 is scheduled to begin in 2019Q1.
